Skip to main content
Chabiotech Co.,Ltd. logo

Chabiotech Co.,Ltd. — Investor Relations & Filings

Ticker · 085660 ISIN · KR7085660009 KO Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2024-03-29 Declaration of Voting R…
Country KR South Korea
Listing KO 085660

About Chabiotech Co.,Ltd.

http://en.chabio.com/

Chabiotech Co., Ltd. is a biotechnology company specializing in the research and development of cell and gene therapies for rare cancers and incurable diseases. The company's core activities include advancing its therapeutic pipelines and providing global Contract Development and Manufacturing Organization (CDMO) services for advanced biopharmaceuticals, including full-scale GMP production and testing. Chabiotech also operates bio-banking services, such as cord blood and immune/stem cell storage, utilizing advanced cryopreservation technology. Its diversified business segments extend to genomics for precision medicine, healthcare IT solutions that integrate AI and Big Data, comprehensive wellness programs, and specialized healthcare consulting.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of a General Meeting of Shareholders (AGM). It details the approval of financial statements, dividend resolutions, board member appointments, and other agenda items voted upon during the meeting held on 2024-03-29. This fits the definition of a Declaration of Voting Results (DVA).
2024-03-29 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted by Cha Biotech. It provides a summary of audit opinions, financial highlights (assets, liabilities, revenue, profit/loss), and auditor information. While it contains financial data, it is a standard regulatory disclosure announcement regarding the completion and submission of the audit report to the exchange, rather than the full annual report document itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2023
2024-03-20 Korean
사업보고서 (2023.12)
Annual Report Classification · 100% confidence The document is titled '사업보고서' (Business Report) for the 22nd fiscal year (2023), which is the standard terminology for an Annual Report in South Korea (equivalent to a 10-K). It contains detailed company information, management structure, and business history, and is addressed to the Financial Services Commission and the Korea Exchange. It is a comprehensive annual filing, not an announcement or a summary. FY 2023
2024-03-20 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Cha Biotech. It outlines the date, location, agenda items (such as financial statement approval, articles of incorporation changes, and director appointments), and voting procedures. This document serves as the official solicitation and information statement provided to shareholders prior to the meeting, which falls under the Proxy Solicitation & Information Statement category.
2024-03-14 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted by Cha Biotech regarding the scheduling of its Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the reasons for choosing this date despite efforts to avoid it. Since it is a regulatory announcement regarding meeting logistics and compliance rather than the meeting materials themselves or a voting result, it falls under the general regulatory filing category.
2024-03-14 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of Annual General Meeting' (주주총회소집공고) for Cha Biotech, issued on March 14, 2024. It contains the meeting agenda, voting procedures (including electronic voting), and detailed management information regarding board activities, remuneration, and business operations as required by Korean commercial law for shareholder meetings. This document is a standard proxy statement/notice for an AGM.
2024-03-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.